研究成果 |
主持科研项目: 1. 三亚市科技创新专项2022KJCX32 基于肠道菌群研究糖尿病状态下氯吡格雷抵抗的作用机制 2023/7-2025/7 38万元 在研 参与 2. 国家科技重大专项 2018ZX09721002007高纯mPEG衍生物及PEG伊立替康关键技术研究2017/4-2021/12 59万元，结题 主持 3. 沈阳协合生物制药股份有限公司，金葡菌肠毒素（SEC2）改构蛋白2M-118口服给药药效学预实验研究 2018/1-2019/1, 20万元，结题 主持 4. 国家自然科学基金.81673510，基于HDACs调控的丙戊酸肝毒性机制及其生物标记物研究，2017/01-2020/12, 54万元，结题 参与 5. 吉林省教育厅“十三五”科学技术研究项目 吉教科合字[2016] 436号 抗癫痫药物VPA诱发肝损伤的血清生物标记物和遗传标记物研究, 2016/1-2018/12，3万元，结题 主持 6. 吉林省科技厅基础研究项目 20150101185JC抗癫痫药物拉莫三嗪个体化治疗的遗传标记物研究2015/1-2017/12，10万元，结题 主持 代表性论文： 1. Xinrui Yan , Linfeng Ma , Xue Chen , Jing Ren , Yu Zhai, Ting Wu , Yu Song , Xiaojiao Li* , Yingjie Guo*. Ferroptosis promotes valproate-induced liver steatosis in vitro and in vivo. Food Chem Toxicol. 2024 Aug 13:192:114926. 2. Song W, Yan X, Zhai Y, Ren J, Wu T, Guo H, Song Y, Li X, Guo Y*. Probiotics attenuate valproate-induced liver steatosis and oxidative stress in mice. PLoS One. 18(11):e0294363. 2023 3. Wang Y, Liu Y, Yao H, Chen X, Sun Y*, Guo Y*. Decreased plasma exposure of clopidogrel active metabolite in rats after long-term treatment with clopidogrel. Biopharm Drug Dispos. 44(2):129-136.2023 4.Chen X, Liu Y, Yao H, Song W, Song Y, Gu J, Guo Y*. Antibiotics-induced disruption of gut microbiota increases systemic exposure of clopidogrel active metabolite in type 2 diabetic rats. Drug Metab Dispos. 2022 50 (9) 1142-1150. 5. Ma L, Wang Y, Chen X, Zhao L, Guo Y*. Involvement of CYP2E1-ROS-CD36/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro. Toxicology. 1(445):152585. 2020 6. Yao H, Gu J, Shan Y, Wang Y, Chen X, Sun D, Guo Y*. Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats. Biochem Pharmacol. 180:114142. 2020 7. Yao HW, Bai RF, Ren TM, Wang YN, Gu JK*, Guo YJ*. Enhanced platelet response to clopidogrel in Zucker diabetic fatty ratsdue to impaired clopidogrel inactivation by carboxylesterase 1 and increased exposure to active metabolite. Drug Metabolism and Disposition 47(8):794-801. 2019 8. Ma L, Pan Y, Sun M, Shen H, Zhao L, Guo Y*. Catalase C-262T Polymorphism Is a Risk Factor for Valproic Acid-Induced Abnormal Liver Function in Chinese Patients With Epilepsy.Ther Drug Monit. 41(1):91-96. 2019. 9. Zhou J, Liu M, Chen Y, Xu S, Guo Y*, Zhao L*. Cucurbitacin B suppresses proliferation of pancreatic cancer cells by ceRNA: Effect of miR-146b-5p and lncRNA-AFAP1-AS1.J Cell Physiol. 234(4):4655-4667. 2019. |
